Put companies on watchlist
MPH Health Care AG
ISIN: DE000A289V03
WKN: A289V0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MPH Health Care AG · ISIN: DE000A289V03 · EQS - Company News (41 News)
Country: Germany · Primary market: Germany · EQS NID: 1203367
02 June 2021 08:30AM

MPH Health Care AG: result Q1-2021


DGAP-News: MPH Health Care AG / Key word(s): Quarterly / Interim Statement/Miscellaneous
MPH Health Care AG: result Q1-2021

02.06.2021 / 08:30
The issuer is solely responsible for the content of this announcement.


MPH Health Care AG: result Q1-2021

MPH Health Care AG with a good start into the year: EBIT amounts to EUR 22.5 million in Q1. Equity (net asset value) rises to EUR 223.4 million, corresponding to EUR 52.19 per share.

Berlin, 2 June 2021: In the first quarter of 2021, MPH Health Care AG (ISIN: DE000A289V03) benefited from the recovery of the stock market prices of its listed investments and achieved an operating result (EBIT) according to IFRS of EUR 22.5 million (same period previous year: EUR -88.4 million).

Equity increased by 11.0% to EUR 223.4 million (31.12.2020: EUR 201.3 million). Net asset value (NAV) per share increased accordingly from EUR 47.01 to EUR 52.19. The equity ratio as at 31.03.2021 increased slightly to 96.0% (31.12.2020: 95.5%).

The investment M1 Kliniken AG had a successful start into the year 2021 with a significant increase in revenues and earnings in the two business segments "Beauty" and "Trade". Consolidated revenue rose to around EUR 81 million in the first quarter of 2021 (previous year EUR 23 million) and EBITDA to EUR 4.0 million (previous year EUR 1.4 million).

In the Beauty segment, the new year had a slow start (due to the ongoing Corona pandemic) with treatment figures around 20% below the previous year. However, by the end of the quarter, M1 was back to historic peak daily sales and continued to grow. In Q1-2021 as a whole, almost 81 thousand treatments were carried out compared to 73 thousand treatments in the same quarter of the previous year. By the end of May 2021, four new specialist centers had already been opened in the German market. According to current planning, a total of 50 M1 specialist centers are planned by the end of 2021, with further locations also opening in foreign markets.

In the trading segment, the operational optimization of the business activities of HAEMATO AG continued, which was able to report an increase in turnover in the past quarter compared to the previous year. In the process, HAEMATO AG was able to significantly improve its profitability. The share price of M1 Kliniken AG improved from 9.24 euros on 31 December 2020 to 10.85 euros on 31 March 2021.

Our second listed investment CR Capital AG (formerly CR Capital Real Estate AG) was also able to continue on its successful path in 2021 - almost unaffected by the COVID-19 pandemic - and continued to grow profitably. In the first three months, CR Capital was already able to notarially sell 161 residential units with a sales volume of approx. EUR 54 million in the projects Rousseau Park in the Berlin suburbs and Leipzig-Schkeuditz via participation Terrabau. The share price of CR Capital AG has increased from EUR 30.50 on 31 December 2020 to EUR 32.50 on 31 March 2021.

With an increasing easing of the Corona restrictions due to rising vaccination rates and falling case numbers, we are confident about the further development of our investments. All M1 Med Beauty locations in Germany and abroad have been reopened in the meantime, HAEMATO AG is making an important contribution to the Corona pandemic with the sale of medical products for Covid-19 diagnostics, and CR Capital AG has so far been able to record a continually strong demand for affordable residential real estate.

Due to the ongoing Corona pandemic, MPH Health Care AG will make use of the option to invite shareholders to the company's Annual General Meeting scheduled for 15 July 2021 with a shortened notice period of 21 days.

About MPH Health Care AG:
MPH AG is an investment company with a strategic focus on the purchase, development and sale of companies and company shares, especially in growth segments of the health care market. This includes both insurance-financed and privately financed segments. However, MPH also exploits potentials outside the healthcare market from high-growth and high-yield sectors.

MPH Health Care AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.


Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de


02.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MPH Health Care AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: 030 / 863 21 45 60
Fax: 030 / 863 21 45 69
E-mail: info@mph-ag.de
Internet: www.mph-ag.de
ISIN: DE000A289V03, DE000A289VT5
WKN: A289V0
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1203367

 
End of News DGAP News Service

1203367  02.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1203367&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MPH Health Care AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.